Remove category 212 regulatory
article thumbnail

Bluebird’s $2.8M Gene Therapy Zynteglo Wins Landmark FDA Approval for Beta Thalassemia

XTalks

Register for this free webinar to learn why the agile clinical trial model is a great fit for many rare disease categories, how to navigate the regulatory landscape for agile clinical trials in rare diseases, how to design studies and more. Live and On-Demand: Tuesday, October 4, 2022, at 11am EDT (4pm BST/UK).

article thumbnail

The case for AI and machine learning in life sciences

Pharmaceutical Technology

Over the next two years, GlobalData’s thematic research unit shows further advancements in machine learning, falling into three main categories: technology, macroeconomic, and regulatory. Key technology trends include advancements in AI, AI chips, and natural language processing.